Preeclampsia is a major cause of maternal morbidity and mortality, complicating 3-14% of all pregnancies. Pregnancy complicated by antiphospholipid antibodies and preeclampsia in pregnancy share several common characteristics, which suggest that the association between the two conditions is more than coincidental. To assess the level of antiphospholipid antibodies in normal pregnancy and in pregnancy complicated by preeclampsia a case control prospective study carried out in Department of Obstetrics and Gynecology/Baghdad Teaching Hospital/ Medical City/ from January 2012 to January 2013. Seventy-two pregnant women were enrolled into this study, 48 with preeclampsia (mild and severe), and 24 women without hypertension as a control group. Their age ranges from (16-42 years) and gestational age between (24-40 weeks). Antiphospholipid antibodies APLAB (IgG and IgM) and anticardiolipin antibodies ACLAB (IgG and IgM) levels were measured by ELISA (enzyme. linked ImmunoSorbent Assay) in all participates. The study showed elevation of ACLAB IgM in preeclampsia group with mean ±SD of (21.93±16.12), (8.22±1.75) for severe and mild preeclampsia respectively while in the control group it was (6.62± 2.8). This was highly significant in severe preeclampsia when compared to mild and control group. We conclude that there is significantly elevated level of ACLAB IgM in severe preeclampsia when compared to normal pregnancy.
oxygenation and eclampsia is associated with approximately 13%maternal deaths worldwide [2] .
Antiphospholipid antibodies are heterogenous group of autoantibodies directed against anionic phospholipids or phospholipid containing structures [3] .
Although these antibodies may be seen in normal pregnancies but there are evidences that these antibodies are associated with complications in pregnancy as preeclampsia, thrombosis, placental infarctions and recurrent fetal deaths. The presence of these antibodies in pregnant women raises the possibility of obstetric and thrombotic complications [4] . The causal relationship between antiphospholipid antibodies and preeclampsia has not yet been proven [5] . The aim of this study is to assess the level of antiphospholipid antibodies in normal pregnancy and in pregnancy complicated by preeclampsia.
Patients and Methods

Study Design & Setting
This study is a case-control study, 
Inclusion criteria:
The study groups include:
I. Preeclampsia groups; were (48) subdivided into two subgroups: 
Statistical analysis
The significance of difference for more than two groups and using independent student-t-test for difference between two means, while different percentages (qualitative data from different preeclampsia groups and from control group) were tested using Pearson chisquare test (X 2 -test). Statistical significance was considered whenever the P-value was less than 0.05.
Results
A total of 72 primigravida women in their third trimester of pregnancy were included in our study. The demographic characteristics of the three groups included in the study are not statistically different in the age and gestational age. Table 3 The mean ±SD of APLAB in three different groups 
Figure 1
The mean of ACLAB IgM in different groups
Discussion
The relationship between APS and an increased risk of developing preeclampsia is known; however, whether there is an association between high titers of APLAB and preeclampsia in the absence of APS is controversy [6] .
In this study, we compared between classes of antiphospholipid antibodies and anticardiolipin antibodies (ACLAB) and we study which one is increased in [6, 7] especially before 34 weeks of gestation as they found that 20% of women with severe preeclamsia < 34 weeks of gestation has high level of APLAB [8] .
Other studies failed to show this association and conclude that the prevalence of APLAB among preeclampsia women is low [9, 10, 11] . 
